Equillium (NASDAQ:EQ) COO Christine Zedelmayer Sells 9,821 Shares

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 9,821 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $2.70, for a total value of $26,516.70. Following the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $168,982.20. This represents a 13.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The shares were sold at an average price of $2.80, for a total value of $240,833.60.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The shares were sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total value of $362,438.00.

Equillium Price Performance

NASDAQ:EQ opened at $2.90 on Friday. Equillium, Inc. has a 12 month low of $0.27 and a 12 month high of $3.10. The firm has a market capitalization of $183.36 million, a PE ratio of -9.06 and a beta of 1.67. The business’s fifty day moving average price is $2.11 and its 200 day moving average price is $1.64.

Equillium (NASDAQ:EQ) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). As a group, equities analysts anticipate that Equillium, Inc. will post -0.24 EPS for the current year.

Institutional Trading of Equillium

A number of institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its stake in Equillium by 10.8% during the first quarter. Janus Henderson Group PLC now owns 6,494,571 shares of the company’s stock valued at $12,957,000 after purchasing an additional 632,359 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in Equillium by 0.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company’s stock valued at $8,693,000 after purchasing an additional 48,090 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Equillium during the third quarter valued at approximately $5,018,000. Aberdeen Group plc raised its holdings in shares of Equillium by 523.6% during the fourth quarter. Aberdeen Group plc now owns 2,366,688 shares of the company’s stock valued at $3,668,000 after acquiring an additional 1,987,162 shares during the period. Finally, Balyasny Asset Management L.P. raised its holdings in shares of Equillium by 3.6% during the fourth quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company’s stock valued at $3,218,000 after acquiring an additional 72,602 shares during the period. 27.05% of the stock is owned by institutional investors and hedge funds.

Equillium News Roundup

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Analysts Set New Price Targets

A number of equities analysts have commented on EQ shares. Zacks Research upgraded shares of Equillium to a “hold” rating in a report on Thursday, February 26th. Stifel Nicolaus set a $5.00 price objective on shares of Equillium in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research report on Friday, March 27th. Leerink Partners upgraded shares of Equillium from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $1.00 to $6.00 in a research report on Thursday. Finally, Wall Street Zen cut shares of Equillium from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.57.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.